







an Open Access Journal by MDPI

Epigenetics and Novel Opportunities for Precision Medicine and Personalized Therapy of Major Cardiovascular Diseases

Guest Editors:

Dr. Giuditta Benincasa

Department of Advanced Medical and Surgical Sciences (DAMSS), University of Campania "Luigi Vanvitelli", 80138 Naples, Italy

Prof. Dr. Paola Bontempo

Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Via L. De Crecchio 7, 80138 Naples, Italy

Dr. Malik Bisserier

Cardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

Deadline for manuscript submissions: **closed (30 June 2023)**

Message from the Guest Editors

The first goal of this Special Issue is to collect big data generated from epigenome-wide association studies (EWAS) in order to identify novel molecular routes involved in the pathogenesis of major cardiovascular diseases that have the highest potential of being translated into biomarkers for clinical practice. Our second aim is to compile data on natural compounds, which may act as "epidrugs" able to prevent or reverse cardiac damage via remodeling the epigenome, mainly in cardiac and endothelial cells.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research. biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us